• Must have received two or three previous induction/re-induction regimens.
• Patients younger than 65 years should have received previous treatment with cytarabine.
• Limited slots available

Clavis CBCI-208

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients with Late Stage Acute Myeloid Leukemia.

• Relapse must occur at least 90 days to 24 months after the first CR or CRp
• Cannot have relapsed <= 90 days after any induction or consolidation therapy containing a cumulative dose of >= g/m2 cytarabine
• Refractory patients' prior induction therapy had to include at least 1 cycle of an anthracycline and cytarabine-based regimen.
• Acute Promyelocytic Leukemia (APL) excluded

Sunesis CBCI-180

A Phase 3,Randomized Controled, Double-Blind, Multinational Clinical Study of the Efficacy and safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)

• Patients must have AML or ALL as defined by WHO criteria,
• Patient must have High-grade MDS, defined as >10% blasts.
• Low grad MDS, defined as ≤ 10blasts

Exclusions: 

• Acetaminophen 
• Moderate & Strong CYP3A4 inhibitors
• CYP3A4 inducers
• Coumadin, Heparin, Aspirin
• Diarrhea > Grade 1

Millennium - CBCI-214

An Open-Label,Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia